BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11581235)

  • 1. Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones.
    Ruiz J; Jurado A; Garcia-Méndez E; Marco F; Aguilar L; Jiménez de Anta MT; Vila J
    J Antimicrob Chemother; 2001 Oct; 48(4):545-8. PubMed ID: 11581235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene.
    Ruiz J; Marco F; Sierra JM; Aguilar L; Garcia-Mendez E; Mensa J; Jiménez De Anta MT; Vila J
    Int J Antimicrob Agents; 2003 Jul; 22(1):73-6. PubMed ID: 12842332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
    Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
    Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 91 clinical isolates of Neisseria gonorrhoeae in Japan.
    Shigemura K; Shirakawa T; Okada H; Hinata N; Acharya B; Kinoshita S; Kofuku T; Kawabata M; Kamidono S; Arakawa S; Gotoh A
    Sex Transm Dis; 2004 Mar; 31(3):180-4. PubMed ID: 15076932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Activity of Sitafloxacin and Additional Newer Generation Fluoroquinolones Against Ciprofloxacin-Resistant Neisseria gonorrhoeae Isolates.
    Hamasuna R; Ohnishi M; Matsumoto M; Okumura R; Unemo M; Matsumoto T
    Microb Drug Resist; 2018; 24(1):30-34. PubMed ID: 28581359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
    Gillespie SH; Voelker LL; Ambler JE; Traini C; Dickens A
    Microb Drug Resist; 2003; 9(1):17-24. PubMed ID: 12705679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistant strains and a comparison of agar dilution and Etest methods.
    Jones RN; Deshpande LM; Erwin ME; Barrett MS; Beach ML
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():67-70. PubMed ID: 10824035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of gemifloxacin (SB-265805), a newer fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae, including fluoroquinolone-resistant isolates.
    Tanaka M; Tunoe H; Mochida O; Kanayama A; Saika T; Kobayashi I; Naito S
    Diagn Microbiol Infect Dis; 2000 Oct; 38(2):109-13. PubMed ID: 11035242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-frequency of quinolone-resistant Neisseria gonorrhoeae in Austria with a common pattern of triple mutations in GyrA and ParC genes.
    Uthman A; Heller-Vitouch C; Stary A; Bilina A; Kuchinka-Koch A; Söltz-Szöts J; Tschachler E
    Sex Transm Dis; 2004 Oct; 31(10):616-8. PubMed ID: 15389000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of a new fluoroquinolone, DU-6859a, against quinolone-resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV.
    Deguchi T; Yasuda M; Nakano M; Kanematsu E; Ozeki S; Ishihara S; Saito I; Kawada Y
    J Antimicrob Chemother; 1997 Feb; 39(2):247-9. PubMed ID: 9069547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
    Shultz TR; Tapsall JW; White PA
    Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.
    Yun HJ; Min YH; Jo YW; Shim MJ; Choi EC
    Int J Antimicrob Agents; 2005 Apr; 25(4):334-7. PubMed ID: 15784314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
    Heaton VJ; Ambler JE; Fisher LM
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in gyrA, gyrB, parC, and parE in quinolone-resistant strains of Neisseria gonorrhoeae.
    Lindbäck E; Rahman M; Jalal S; Wretlind B
    APMIS; 2002 Sep; 110(9):651-7. PubMed ID: 12529019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation between mutation of GyrA and ParC genes and quinolone resistance in Neisseria gonorrhoeae].
    Xie P; Mi ZH; Li Q; Zhang J; Xiao CY
    Zhonghua Nan Ke Xue; 2003; 9(4):275-8. PubMed ID: 12931370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High occurrence of simultaneous mutations in target enzymes and MtrRCDE efflux system in quinolone-resistant Neisseria gonorrhoeae.
    Dewi BE; Akira S; Hayashi H; Ba-Thein W
    Sex Transm Dis; 2004 Jun; 31(6):353-9. PubMed ID: 15167645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the gyrA and parC genes of quinolone-resistant Neisseria gonorrhoeae isolates in India.
    Kulkarni S; Bala M; Sane S; Pandey S; Bhattacharya J; Risbud A
    Int J Antimicrob Agents; 2012 Dec; 40(6):549-53. PubMed ID: 23063097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.